IL33 and allergic disease: These data in combination with our recent observation that MCs can degranulate directionally into the bloodstream [15] suggest that MCs co‐activated by ATP and IL‐33 might be an attractive therapeutic target to dampen cytokine storm syndromes, shock symptoms or allergic reactions.